Ocular Therapeutix will discuss Q4 2024 results during a conference call on March 3, 2025, at 8 AM ET.
Quiver AI Summary
Ocular Therapeutix, Inc. announced a conference call and webcast on March 3, 2025, at 8:00 AM ET to discuss its recent business developments and financial results for the fourth quarter and full year ending December 31, 2024. Participants can join via U.S. and international dial-in numbers or access the webcast through the company's Investor Relations website. Ocular Therapeutix focuses on innovative treatments for retinal diseases, including its Phase 3 clinical trial product AXPAXLI for wet age-related macular degeneration, and its FDA-approved product DEXTENZA for ocular inflammation. The company's other product candidate, PAXTRAVA, is in a Phase 2 trial for open-angle glaucoma.
Potential Positives
- Ocular Therapeutix plans to discuss recent business progress and financial results, indicating an active engagement with stakeholders and transparency in reporting.
- The webcast will provide access to information about the company's performance and future prospects, which can help strengthen investor confidence.
- AXPAXLI, Ocular’s product candidate for retinal disease, is in Phase 3 clinical trials for wet AMD, highlighting the company's advancing pipeline of potential treatments.
- Ocular’s existing commercial product DEXTENZA® is FDA-approved, showcasing their capability to bring innovative therapies to market successfully.
Potential Negatives
- There is no information indicating a successful outcome or progress of the ongoing Phase 3 clinical trials for AXPAXLI, which may raise concerns among investors about the viability of this key product candidate.
FAQ
What is the purpose of Ocular Therapeutix's upcoming conference call?
The conference call will discuss recent business progress and financial results for Q4 and full year 2024.
When is the Ocular Therapeutix conference call scheduled?
The conference call is set for Monday, March 3, 2025, at 8:00 AM ET.
How can I access the Ocular Therapeutix webcast?
You can access the webcast via the Ocular Therapeutix website in the Events and Presentations section or via the provided link.
What is AXPAXLI and its current trial status?
AXPAXLI is Ocular's candidate for retinal disease, currently in Phase 3 trials for wet age-related macular degeneration.
Who can I contact for more information about Ocular Therapeutix?
You can contact Bill Slattery, Vice President of Investor Relations, via email at bslattery@ocutx.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OCUL Insider Trading Activity
$OCUL insiders have traded $OCUL stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $OCUL stock by insiders over the last 6 months:
- PRAVIN DUGEL (See Remarks) sold 20,680 shares for an estimated $186,326
- DONALD NOTMAN (See Remarks) has made 0 purchases and 2 sales selling 17,420 shares for an estimated $136,239.
- JEFFREY S. HEIER (Chief Scientific Officer) sold 2,948 shares for an estimated $26,561
- PETER KAISER (Chief Development Officer) sold 2,897 shares for an estimated $26,101
- SANJAY NAYAK (Chief Strategy Officer) sold 1,814 shares for an estimated $16,326
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$OCUL Hedge Fund Activity
We have seen 86 institutional investors add shares of $OCUL stock to their portfolio, and 70 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ASSENAGON ASSET MANAGEMENT S.A. removed 2,825,756 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $24,131,956
- PERCEPTIVE ADVISORS LLC removed 2,245,973 shares (-67.6%) from their portfolio in Q4 2024, for an estimated $19,180,609
- BRAIDWELL LP removed 2,239,770 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $19,127,635
- POINT72 ASSET MANAGEMENT, L.P. added 895,304 shares (+43.9%) to their portfolio in Q4 2024, for an estimated $7,645,896
- OPALEYE MANAGEMENT INC. removed 682,500 shares (-13.6%) from their portfolio in Q4 2024, for an estimated $5,828,549
- SUMMER ROAD LLC removed 528,725 shares (-3.7%) from their portfolio in Q4 2024, for an estimated $4,515,311
- TRI LOCUM PARTNERS LP removed 514,642 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $4,477,385
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss recent business progress and financial results for the fourth quarter and full year ended December 31, 2024.
Conference Call and Webcast Information:
Date: Monday, March 3, 2025, at 8:00 AM ET
Participant Dial-In (U.S.): 1 (877) 407-9039
Participant Dial-in (International): 1 (201) 689-8470
Conference ID: 13750940
Webcast Access: Please click
here
The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (axitinib intravitreal hydrogel, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA
®
, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral injection or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA
®
are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
